Company Verrica Pharmaceuticals Inc.

VRCA

US92511W1080

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Verrica Pharmaceuticals Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
6.79 ^USD	-2.72%		-1.88%	-7.24%

Mar. 26	Verrica Pharmaceuticals' Ycanth Gets New Chemical Entity Status, Orange Book Listing	MT
Mar. 26	Verrica Pharmaceuticals Announces that YCANTH? Receives New Chemical Entity Status and Orange Book Listing from the FDA	CI

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.

Number of employees: 100

USD in Million	2022	Weight	2023	Weight	Delta
Novel Topical Solution of Cantharidin 100.0 %	9	100.0 %	5	100.0 %	-43.27%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	9	100.0 %	5	100.0 %	-43.27%

Managers	Title	Age	Since
Ted White CEO	Chief Executive Officer	59	17-11-30
Terence Kohler DFI	Director of Finance/CFO	46	21-07-15
Christopher Hayes CMP	Compliance Officer	60	18-08-31
Gary Goldenberg CTO	Chief Tech/Sci/R&D Officer	47	18-04-30
Joe Bonaccorso PRN	Corporate Officer/Principal	60	18-01-31

Members of the board	Title	Age	Since
Mark Prygocki BRD	Director/Board Member	58	18-04-30
Paul Manning CHM	Chairman	68	15-11-30
Craig Ballaron BRD	Director/Board Member	63	19-06-12
Sean Stalfort BRD	Director/Board Member	54	15-11-30
Ted White CEO	Chief Executive Officer	59	17-11-30
Lawrence Eichenfield BRD	Director/Board Member	66	20-06-30
Gary Goldenberg CTO	Chief Tech/Sci/R&D Officer	47	18-04-30
Diem Nguyen BRD	Director/Board Member	52	20-06-08

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	42,525,197	18,478,346 ( 43.45 %)	105,144 ( 0.2473 %)	43.45 %

Name	Equities	%	Valuation
Paul Manning 36.75 %	15,589,481	36.75 %	92 M $
Perceptive Advisors LLC 16.74 %	7,099,182	16.74 %	42 M $
Avoro Capital Advisor LLC 9.430 %	3,999,999	9.430 %	24 M $
Fidelity Management & Research Co. LLC 3.558 %	1,509,063	3.558 %	9 M $
Vanguard Fiduciary Trust Co. 2.973 %	1,261,101	2.973 %	7 M $
BlackRock Advisors LLC 2.552 %	1,082,727	2.552 %	6 M $
Sean Stalfort 1.651 %	700,205	1.651 %	4 M $
Geode Capital Management LLC 1.013 %	429,677	1.013 %	3 M $
STATE STREET CORPORATION 0.9177 %	389,267	0.9177 %	2 M $
BML Capital Management LLC 0.4243 %	180,000	0.4243 %	1 M $

Verrica Pharmaceuticals, Inc.

44 West Gay Street Suite 400

19380, West Chester

+484 453 3300

http://www.verrica.com

address Verrica Pharmaceuticals Inc.(VRCA)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.79 USD

Average target price

13.6 USD

Spread / Average Target

+100.29%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
VERRICA PHARMACEUTICALS INC.	-7.24%	288M
ELI LILLY AND COMPANY	+25.46%	659B
NOVO NORDISK A/S	+25.38%	557B
JOHNSON & JOHNSON	-4.86%	359B
MERCK & CO., INC.	+16.44%	322B
ABBVIE INC.	+8.34%	297B
ASTRAZENECA PLC	+6.13%	215B
NOVARTIS AG	+2.93%	210B
ROCHE HOLDING AG	-7.65%	200B
PFIZER, INC.	-8.79%	149B

Other Pharmaceuticals